Antimicrobial peptides and methods of using the same
Aspects of the present invention relate to peptides having antimicrobial activity. In certain aspects, the invention relates to peptides having potent antimicrobial activity, broad-spectrum antimicrobial activity, and/or the ability to kill otherwise antibiotic-resistant microbes, or microbes protected by biofilms.
1. A peptide, comprising:
a) a peptide sequence selected from RP550-557 (SEQ ID NO: 1 to SEQ ID NO: 8), RP559-562 (SEQ ID NO: 10 to SEQ ID NO: 13), RP566 (SEQ ID NO: 17) or RP567 (SEQ ID NO: 18);
b) a sequence having at least 90% sequence identity with the sequence defined in a); or
c) a sequence having three or less amino acid substitutions relative to the sequence defined in a), wherein the three or less amino acid substitutions are conservative amino acid substitutions according to Table 3.
2. The peptide of claim 1 , comprising:
a) a peptide sequence selected from RP550-557 (SEQ ID NO: 1 to SEQ ID NO: 8), RP559-562 (SEQ ID NO: 10 to SEQ ID NO: 13), RP566 (SEQ ID NO: 17) or RP567 (SEQ ID NO: 18); or
b) a sequence having three or less amino acid substitutions relative to the sequence defined in a), wherein the three or less amino acid substitutions consist of substitution of a cationic amino acid of the sequence with an alternative cationic amino acid residue.
3. The peptide of claim 1 , wherein the peptide sequence defined in a) is RFCWKVCYKGICFKKCK (RP557) (SEQ ID NO: 8).
4. The peptide of claim 1 , wherein the peptide sequence defined in a) is FOLOAOIOVOLOAOIOL (RP555) (SEQ ID NO: 6).
5. The peptide of claim 1 , wherein the peptide sequence defined in a) is RWCFKVCYKGICYKKCK (RP560) (SEQ ID NO: 11).
6. The peptide of claim 1 , wherein the peptide sequence defined in a) is FKIOARLCLGOFCIOARLK (RP550) (SEQ ID NO: 1).
7. The peptide of claim 1 , wherein the peptide sequence defined in a) is FIOKFAKOFKOFIOKFAKFAFAF (RP551) (SEQ ID NO: 2).
8. The peptide of claim 1 , wherein the peptide sequence defined in a) is FAFAFKAFKKAFKOFOOAFOOAF (RP552) (SEQ ID NO: 3).
9. The peptide of claim 1 , wherein the peptide sequence defined in a) is FOIKARFOVRARLOLKI (RP553) (SEQ ID NO: 4).
10. The peptide of claim 1 , wherein the peptide sequence defined in a) is FOLOAOIKVKLOAOIOL (RP556) (SEQ ID NO: 7).
11. The antimicrobial peptide of claim 1 , comprising a peptide sequence having at least 90% sequence identity with a sequence selected from RP550-557 (SEQ ID NO: 1 to SEQ ID NO: 8), RP559-562 (SEQ ID NO: 10 to SEQ ID NO: 13), RP566 (SEQ ID NO: 17) or RP567 (SEQ ID NO: 18).
12. The peptide of claim 1 , comprising a peptide sequence selected from:
OFCWOVCYOGICFOOCO (RP561) (SEQ ID NO: 12); and
OWCFOVCYOGICYOOCO (RP559) (SEQ ID NO: 10).
13. A pharmaceutical composition, comprising the peptide of claim 1 and a pharmaceutically acceptable carrier.
14. The pharmaceutical composition of claim 13 , wherein the composition is formulated for oral administration, parenteral administration, inhalation administration or topical administration.
15. The pharmaceutical composition of claim 13 , wherein the composition is formulated for oral administration and further comprises an enteric coating.
16. The pharmaceutical composition of claim 13 , wherein the composition is formulated for topical delivery in a form selected from a gel suspension, a cream, microneedle, and infused into a bandage or topical patch.
17. The pharmaceutical composition of claim 13 , wherein the composition is formulated for inhalation.
18. The pharmaceutical composition of claim 13 , further comprising an additional bioactive agent.
19. The pharmaceutical composition of claim 18 , wherein the additional bioactive agent is selected from an antimicrobial agent, an anti-inflammatory drug, an anti-nausea drug, an anti-pain medication, and combinations thereof.
20. The pharmaceutical composition of claim 13 , wherein the composition is formulated to be coated on the surface of an implantable medical device.
21. A method of reducing the likelihood of a microbial infection in a subject in need thereof, the method comprising administering a pharmaceutical composition according to claim 13 to the subject.
22. The method of claim 21 , wherein the pharmaceutical composition is administered to the subject orally, parenterally, via inhalation or topically.
23. The method of claim 21 , wherein the pharmaceutical composition is administered to the subject by applying the composition to a surface of a medical device prior to inserting the medical device into the subject.
24. The method of claim 21 , wherein the subject is selected from a human, a domesticated animal, a farm animal and a zoo animal.